Susquehanna International Group, LLP Ovid Therapeutics Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$1.69 - $3.31 $23,660 - $46,340	-14,000 Reduced 55.34%	11,300 $24,000
Q1 2022 May 16, 2022	SELL	$2.65 - $3.49 $246,185 - $324,221	-92,900 Reduced 78.6%	25,300 $79,000
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $250,087 - $298,027	-79,900 Reduced 40.33%	118,200 $379,000
Q3 2021 Nov 15, 2021	SELL	$3.31 - $4.04 $22,839 - $27,876	-6,900 Reduced 3.37%	198,100 $666,000
Q2 2021 Aug 11, 2021	BUY	$3.3 - $4.49 $73,590 - $100,127	22,300 Added 12.21%	205,000 $802,000

Q1 2021 May 17, 2021	BUY	$2.42 - $4.47 $417,934 - $771,969	172,700 Added 1727.0%	182,700 $734,000
Q4 2020 Feb 16, 2021	SELL	$2.28 - $6.84 $82,308 - $246,924	-36,100 Reduced 78.31%	10,000 $23,000
Q3 2020 Nov 16, 2020	SELL	$5.39 - $8.24 $126,125 - $192,816	-23,400 Reduced 33.67%	46,100 $265,000
Q2 2020 Aug 14, 2020	BUY	$2.67 - $7.91 $185,565 - $549,745	69,500 New	69,500 $512,000

43.2M

5.9K

300

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $52.8M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.